ATHE
Alterity Therapeutics Limited
There isn't enough reported data to score ATHE yet.
ATHE Fundamentals
| Metric | Status |
|---|---|
| Unavailable | |
| Under pressure | |
| Unavailable | |
| Unavailable |
ATHE's profitability is currently under pressure. There isn't enough data to rate its revenue, cash flow and balance sheet.
ATHE PE Valuation
ATHE has no meaningful PE right now: it lost money over the past year.
ATHE Forward outlook
There aren't enough analyst estimates for ATHE to show an outlook.
ATHE Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q2 2025 | -$0.13 | +$0.23 |
ATHE Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q2 2023 | $1M | -45% |
| Q4 2022 | $1.6M | +1.1% |
| Q2 2022 | $1.9M | +13% |
| Q4 2021 | $1.6M | +23% |
| Q4 2020 | $1.3M | +3.7% |
| Q4 2019 | $1.3M | -24% |
| Q2 2019 | $1.7M | +1155% |
| Q2 2018 | $137.7K | -84% |
ATHE's revenue is growing: $1M last quarter, down 38% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q2 2023 | -508% | -106 points |
| Q4 2022 | -451% | -5.7 points |
| Q2 2022 | -378% | N/A |
| Q4 2021 | -279% | +31 points |
| Q2 2021 | -402% | -121 points |
| Q4 2020 | -445% | -214 points |
| Q4 2019 | -310% | -91 points |
| Q2 2019 | -281% | -63 points |
ATHE's operating margin was −508% last quarter, down 106 points from the same quarter a year ago.
ATHE Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q2 2024 | -$8.6M | -$4.4M |
| Q2 2023 | -$4.2M | -$4M |
| Q4 2022 | -$3.5M | +$2.4M |
| Q2 2022 | -$236.2K | +$11.6M |
| Q4 2021 | -$5.9M | -$918.5K |
| Q2 2021 | -$11.9M | -$7.2M |
| Q4 2020 | -$5M | -$3.2M |
| Q2 2020 | -$4.7M | -$80.6K |
ATHE has burned cash in almost every quarter: −$17M over the past year, against −$28M the year before.
ATHE Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +75% | +2.7B shares |
| 1 year | +159366% | +6.4B shares |
| 3 years | +11882% | +6.3B shares |
| 5 years | +952204% | +6.4B shares |
| Available history | +1686795% | +6.4B shares |
ATHE has 6.4B diluted shares, up 159366% from a year ago.
| Quarter | Spent |
|---|---|
| Q2 2023 | — |
| Q4 2022 | — |
| Q2 2022 | — |
| Q2 2021 | — |
| Q2 2020 | — |
| Q4 2019 | — |
| Q2 2019 | — |
| Q4 2018 | — |
ATHE Net Leverage
ATHE's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
ATHE Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 29.3 | Oversold |
| Stochastic | 7.2 | Oversold |
ATHE's weekly RSI is 29 (oversold) and its Stochastic is 7 (oversold).
ATHE PE vs Healthcare Sector
ATHE has no meaningful PE right now: it lost money over the past year.
ATHE Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $2.70 | 22% below |
| 20 week MA | $3.86 | 46% below |
| 50 week MA | $3.80 | 45% below |
| 100 week MA | $3.98 | 47% below |
| 200 week MA | $3.12 | 33% below |
ATHE is in a downtrend: it's below all five of its weekly moving averages, and 33% below its 200-week average.
ATHE Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $8.40 | $14.5 | +73% |
| 2021 | $14.5 | $8.20 | -43% |
| 2022 | $8.20 | $3.00 | -63% |
| 2023 | $3.00 | $2.49 | -17% |
| 2024 | $2.49 | $3.14 | +26% |
| 2025 | $3.14 | $3.17 | +1% |
| 2026 YTD | $3.17 | $2.10 | -34% |
ATHE has finished lower in three of the last six years. It's down 34% so far in 2026.